Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer
A Prospective, Multicenter, Randomized Controlled Study of Disitamab Vedotin Plus Toripalimab With or Without Pelvic Lymph Node Dissection for Bladder-Sparing Treatment in Patients With cT2-3N0M0 Bladder Urothelial Carcinoma
調査の概要
状態
詳細な説明
Muscle-invasive bladder cancer is commonly treated with radical cystectomy; however, bladder-sparing strategies are needed for selected patients who decline cystectomy. This study evaluates a bladder-sparing strategy based on maximal transurethral resection of bladder tumor, disitamab vedotin plus toripalimab, and the addition of standardized pelvic lymph node dissection.
Participants will be randomized to receive disitamab vedotin plus toripalimab with or without pelvic lymph node dissection after maximal transurethral resection of bladder tumor. Tumor response will be assessed by imaging, cystoscopy or transurethral resection/biopsy when clinically indicated, and urine cytology. Participants who meet bladder-sparing criteria will enter bladder-intact follow-up according to the protocol. Safety, survival, quality of life, treatment cost, and exploratory biomarkers will also be evaluated.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Hailong Hu
- 電話番号:+86 13662096232
- メール:huhailong@tmu.edu.cn
研究連絡先のバックアップ
- 名前:Peng Li
- 電話番号:+86 18935803489
- メール:lipeng990220@tmu.edu.cn
研究場所
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300211
- The Second Hospital of Tianjin Medical University
-
コンタクト:
- Peng Li
- 電話番号:+86 18935803489
- メール:lipeng990220@tmu.edu.cn
-
コンタクト:
- Hailong Hu, MD,PhD
- 電話番号:+86 13662096232
- メール:huhailong@tmu.edu.cn
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Male or female participants aged 18 years or older.
- Histologically confirmed bladder urothelial carcinoma.
- Clinical stage cT2-3N0M0 according to the AJCC 8th edition TNM staging system.
- HER2 expression of IHC 2+ or higher.
- Participants who decline radical cystectomy as assessed by the investigator.
- Adequate organ function as defined in the study protocol.
- Ability to understand and willingness to sign written informed consent.
Exclusion Criteria:
- Known allergy or hypersensitivity to disitamab vedotin, toripalimab, their excipients, or other monoclonal antibodies.
- Prior radiotherapy for bladder cancer.
- Prior anticancer treatment that may affect efficacy assessment, as defined in the study protocol.
- Pregnant or breastfeeding women.
- Any serious uncontrolled disease or medical condition that, in the investigator's judgment, would make participation inappropriate.
- Participation in another interventional clinical trial that may interfere with this study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Disitamab Vedotin Plus Toripalimab With Pelvic Lymph Node Dissection
Participants will receive maximal transurethral resection of bladder tumor followed by disitamab vedotin plus toripalimab and standardized pelvic lymph node dissection.
|
Disitamab vedotin will be administered in combination with toripalimab according to the study protocol.
Toripalimab will be administered in combination with disitamab vedotin according to the study protocol.
Maximal transurethral resection of bladder tumor will be performed as part of the bladder-sparing treatment strategy.
Standardized pelvic lymph node dissection will be performed in participants assigned to the PLND arm.
|
|
アクティブコンパレータ:Disitamab Vedotin Plus Toripalimab Without Pelvic Lymph Node Dissection
Participants will receive maximal transurethral resection of bladder tumor followed by disitamab vedotin plus toripalimab without planned pelvic lymph node dissection.
|
Disitamab vedotin will be administered in combination with toripalimab according to the study protocol.
Toripalimab will be administered in combination with disitamab vedotin according to the study protocol.
Maximal transurethral resection of bladder tumor will be performed as part of the bladder-sparing treatment strategy.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
2-year Bladder-intact Event-free Survival Rate
時間枠:24 months after randomization
|
The proportion of participants who remain alive with an intact bladder and without muscle-invasive bladder cancer recurrence, regional lymph node recurrence, distant metastasis, radical cystectomy, or bladder cancer-related death at 24 months after randomization.
|
24 months after randomization
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Clinical Complete Response Rate
時間枠:After completion of induction treatment, up to 12 weeks
|
The proportion of participants who achieve clinical complete response, defined as no visible tumor on imaging, no evidence of malignancy on cystoscopy or TURBT/biopsy when clinically indicated, and negative urine cytology.
For participants undergoing pelvic lymph node dissection, no lymph node metastasis is required.
|
After completion of induction treatment, up to 12 weeks
|
|
Partial Response Rate
時間枠:After completion of induction treatment, up to 12 weeks
|
The proportion of participants with non-muscle-invasive disease, including Ta, T1, or carcinoma in situ, confirmed by urine cytology or pathological biopsy, with no evidence of locally advanced or metastatic disease on imaging.
|
After completion of induction treatment, up to 12 weeks
|
|
Disease Progression Rate
時間枠:Up to 24 months after randomization
|
The proportion of participants with disease progression, defined as muscle-invasive bladder cancer confirmed by pathological biopsy, locally advanced disease, regional lymph node recurrence, distant metastasis, or bladder cancer-related death.
|
Up to 24 months after randomization
|
|
Overall Survival
時間枠:Up to 60 months after randomization
|
Overall survival is defined as the time from randomization to death from any cause.
|
Up to 60 months after randomization
|
|
Incidence and Severity of Adverse Events
時間枠:From the first dose through 30 days after the last dose, up to approximately 19 months
|
The incidence, severity, and relationship to study treatment of adverse events will be assessed according to the Common Terminology Criteria for Adverse Events.
|
From the first dose through 30 days after the last dose, up to approximately 19 months
|
|
Quality of Life Score
時間枠:Baseline to 24 months after randomization
|
Quality of life will be assessed using the EORTC QLQ-C30 questionnaire according to the study protocol.
|
Baseline to 24 months after randomization
|
|
Total Treatment Cost
時間枠:From randomization to the end of follow-up, up to 60 months
|
Total treatment cost will be calculated from randomization to the final follow-up according to the study protocol.
|
From randomization to the end of follow-up, up to 60 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
2-Year Bladder-Intact Event-Free Survival Rate by Baseline HER2 IHC Category
時間枠:24 months after randomization
|
Pretreatment tumor HER2 expression will be assessed by immunohistochemistry and categorized as IHC 2+ or IHC 3+.
The percentage of participants meeting the 2-year bladder-intact event-free survival definition will be estimated separately for each HER2 IHC category.
Bladder-intact event-free survival is defined as being alive with an intact bladder and without muscle-invasive bladder cancer recurrence, regional lymph node recurrence, distant metastasis, radical cystectomy, or bladder cancer-related death.
The unit of measure is percentage of participants.
|
24 months after randomization
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- TMU2H-RC48-TORI-MIBC-2026-035
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。